Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 16, 2023
Period End
December 31, 2022
Security
IDXX
One revenue dollarkept$0.20
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 16, 2023. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2022 10-K shows a company that grew revenue 4.7% reported (7.4% organic) to $3.37 billiona, with diluted EPS of $8.03, down from $8.60 in 2021.

The decline in earnings reflects a $65 millionb in-process R&D charge from two IP licensing arrangements, higher R&D spend overall (R&D rose to 7.6% of revenue from 5.0%), a higher effective tax rate of 21.0% versus 17.5%, and a 3.4% currency headwind to reported revenue growth. Operating income fell 3.6% to $898.8 million, and operating margin compressed from 29.0% to 26.7%. The Companion Animal Group (CAG) drives the business, generating about 91% of revenue, with recurring diagnostic revenue of roughly 79% of consolidated revenue.

Growth was led by price realization and higher VetLab consumable and reference laboratory volumes, while Water grew 6.3% and LPD declined 9.8% on weaker China swine testing. Cash flow from operations fell to $543 millionc from $756 million, driven by heavier inventory build and other working-capital changes, and the company spent $820 million on share repurchases, funded in part by a $432 million increase in credit facility borrowings. Leverage rose meaningfully: total debt including the revolver reached about $1.35 billion, a gross debt to Adjusted EBITDA ratio of 1.27x and net leverage of 1.17x, well inside the 3.5x covenant.

Management guides to a roughly 22% effective tax rate for 2023, a $180 milliond capex plan, and a stronger dollar headwind of about $0.23 per share in 2023. A pending $27.5 million accrual related to an ongoing royalty lawsuit and the possible impact of the Maine PFAS rules are the main contingent items flagged for investors.

Key Highlights

  1. Revenue rose 4.7% reported to $3.37 billion, with 7.4% organic growth driven by price realization and CAG recurring diagnostics, which account for about 79% of revenue.
  2. Diluted EPS fell to $8.03 from $8.60, reflecting a $65 million R&D charge for licensed IP, higher R&D spending, and a 21.0% effective tax rate versus 17.5% in 2021.
  3. Operating income declined 3.6% to $898.8 million, and operating margin compressed to 26.7% from 29.0%.
  4. Operating cash flow fell 28% to $543 million, pressured by a $121.7 million inventory build and higher other working-capital outflows.
  5. Share repurchases totaled roughly $820 million in 2022, with 2.0 million shares bought back, and about 3.0 million shares remain under the 73 million share authorization.
  6. Total debt rose to about $1.35 billion, with $579 million drawn on the $1.25 billion Credit Facility; gross debt to Adjusted EBITDA was 1.27x, well within the 3.5x covenant.
  7. A $27.5 million accrual is held against a royalty underpayment lawsuit with a claim of roughly $50 million, and management says the claim is without merit.

Follow one dollar

Of each $1.00 of revenue in FY2022, IDEXX Laboratories kept $0.20.

  1. Revenue$3.37B100.0%
  2. Cost of revenue−$1.36B40.5%
  3. Gross profit$2.00B59.5%
  4. Operating costs−$1.11B32.8%
  5. Operating income$898.8M26.7%
  6. Interest, other & tax−$219.7M6.5%
  7. Net income$679.1M20.2%
Computed from 10-KFY2022filed February 16, 2023Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2022 revenue went

$3.37B
  • Cost of revenue: $1.36B, 40% of revenue
  • Other operating costs: $850.8M, 25% of revenue
  • Net income: $679.1M, 20% of revenue
  • R&D: $254.8M, 7.6% of revenue
  • Interest, other & tax: $219.7M, 6.5% of revenue

Kept 20% as net income

Full revenue history →

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$3.37B$3.22B+4.7%
Cost of Revenue$1.36B$1.33B+2.8%
Gross Profit$2.00B$1.89B+6.1%
R&D Expenses$254.82M$161.01M+58.3%
Operating Expenses$1.11B——
Operating Income$898.76M$932.03M−3.6%
Interest Expense$39.86M$29.81M+33.7%
Net Income$679.09M$744.84M−8.8%
EPS (Basic)$8.12$8.74−7.1%
EPS (Diluted)$8.03$8.60−6.6%
Shares Outstanding (Basic)83.62M85.20M−1.9%
Shares Outstanding (Diluted)84.60M86.57M−2.3%

Frequently Asked Questions

  1. Why did IDEXX's EPS decline in 2022 even though revenue grew?

    Diluted EPS fell to $8.03 from $8.60 mainly because of a $65 million in-process R&D charge from two IP licensing deals, a $43 million year-over-year increase in R&D expense overall, and a higher effective tax rate (21.0% vs. 17.5%) that reduced tax benefits from share-based compensation. Currency movements also reduced operating profit by about $25 million in 2022 on a net basis.

  2. How much of IDEXX's revenue is recurring?

    About 79% of 2022 consolidated revenue came from recurring diagnostic sales, including IDEXX VetLab consumables, rapid assay kits, and reference laboratory services, along with subscription-based software and service revenue. Recurring revenue carries higher margins than instrument placements, which is central to the investment thesis.

  3. Is IDEXX's debt level a concern for investors?

    Leverage increased in 2022 as the company drew on its credit facility to fund buybacks and to repay a $75 million note. Gross debt to Adjusted EBITDA is 1.27x and net debt to Adjusted EBITDA is 1.17x, far below the 3.5x covenant limit. Borrowings are largely variable-rate (SOFR-based), so a 1% rise in SOFR would add about $5.8 million to annual interest expense.

  4. What are the key risks flagged in the 10-K?

    Key risks include intense competition from larger diagnostics players, consolidation among corporate veterinary hospital owners and buying consortiums that can shift purchasing, reliance on sole-source suppliers (including Ortho for chemistry slides), foreign currency exposure (about 35% of revenue is international), and cybersecurity threats. The company also faces PFAS and chemical regulations in the EU and Maine, plus a pending royalty lawsuit.

  5. What should investors expect for 2023?

    Management expects a stronger U.S. dollar to reduce 2023 revenue by about $16 million, operating profit by about $25 million, and diluted EPS by about $0.23. The effective tax rate is projected near 22%, capital expenditures are planned at about $180 million, and supply chain and inflationary pressures are expected to persist. Management has not given numeric revenue or EPS guidance in this filing.